Cargando…
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439410/ https://www.ncbi.nlm.nih.gov/pubmed/28420696 http://dx.doi.org/10.2337/dc17-er06c |
| _version_ | 1783237944759287808 |
|---|---|
| author | Rosenstock, Julio Aronson, Ronnie Grunberger, George Hanefeld, Markolf Piatti, PierMarco Serusclat, Pierre Cheng, Xi Zhou, Tianyue Niemoeller, Elisabeth Souhami, Elisabeth Davies, Melanie |
| author_facet | Rosenstock, Julio Aronson, Ronnie Grunberger, George Hanefeld, Markolf Piatti, PierMarco Serusclat, Pierre Cheng, Xi Zhou, Tianyue Niemoeller, Elisabeth Souhami, Elisabeth Davies, Melanie |
| author_sort | Rosenstock, Julio |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5439410 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-54394102018-06-01 Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035 Rosenstock, Julio Aronson, Ronnie Grunberger, George Hanefeld, Markolf Piatti, PierMarco Serusclat, Pierre Cheng, Xi Zhou, Tianyue Niemoeller, Elisabeth Souhami, Elisabeth Davies, Melanie Diabetes Care Errata American Diabetes Association 2017-06 2017-04-18 /pmc/articles/PMC5439410/ /pubmed/28420696 http://dx.doi.org/10.2337/dc17-er06c Text en © 2017 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. |
| spellingShingle | Errata Rosenstock, Julio Aronson, Ronnie Grunberger, George Hanefeld, Markolf Piatti, PierMarco Serusclat, Pierre Cheng, Xi Zhou, Tianyue Niemoeller, Elisabeth Souhami, Elisabeth Davies, Melanie Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035 |
| title | Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035 |
| title_full | Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035 |
| title_fullStr | Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035 |
| title_full_unstemmed | Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035 |
| title_short | Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026–2035 |
| title_sort | erratum. benefits of lixilan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the lixilan-o randomized trial. diabetes care 2016;39:2026–2035 |
| topic | Errata |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439410/ https://www.ncbi.nlm.nih.gov/pubmed/28420696 http://dx.doi.org/10.2337/dc17-er06c |
| work_keys_str_mv | AT rosenstockjulio erratumbenefitsoflixilanatitratablefixedratiocombinationofinsulinglarginepluslixisenatideversusinsulinglargineandlixisenatidemonocomponentsintype2diabetesinadequatelycontrolledonoralagentsthelixilanorandomizedtrialdiabetescare20163920262035 AT aronsonronnie erratumbenefitsoflixilanatitratablefixedratiocombinationofinsulinglarginepluslixisenatideversusinsulinglargineandlixisenatidemonocomponentsintype2diabetesinadequatelycontrolledonoralagentsthelixilanorandomizedtrialdiabetescare20163920262035 AT grunbergergeorge erratumbenefitsoflixilanatitratablefixedratiocombinationofinsulinglarginepluslixisenatideversusinsulinglargineandlixisenatidemonocomponentsintype2diabetesinadequatelycontrolledonoralagentsthelixilanorandomizedtrialdiabetescare20163920262035 AT hanefeldmarkolf erratumbenefitsoflixilanatitratablefixedratiocombinationofinsulinglarginepluslixisenatideversusinsulinglargineandlixisenatidemonocomponentsintype2diabetesinadequatelycontrolledonoralagentsthelixilanorandomizedtrialdiabetescare20163920262035 AT piattipiermarco erratumbenefitsoflixilanatitratablefixedratiocombinationofinsulinglarginepluslixisenatideversusinsulinglargineandlixisenatidemonocomponentsintype2diabetesinadequatelycontrolledonoralagentsthelixilanorandomizedtrialdiabetescare20163920262035 AT serusclatpierre erratumbenefitsoflixilanatitratablefixedratiocombinationofinsulinglarginepluslixisenatideversusinsulinglargineandlixisenatidemonocomponentsintype2diabetesinadequatelycontrolledonoralagentsthelixilanorandomizedtrialdiabetescare20163920262035 AT chengxi erratumbenefitsoflixilanatitratablefixedratiocombinationofinsulinglarginepluslixisenatideversusinsulinglargineandlixisenatidemonocomponentsintype2diabetesinadequatelycontrolledonoralagentsthelixilanorandomizedtrialdiabetescare20163920262035 AT zhoutianyue erratumbenefitsoflixilanatitratablefixedratiocombinationofinsulinglarginepluslixisenatideversusinsulinglargineandlixisenatidemonocomponentsintype2diabetesinadequatelycontrolledonoralagentsthelixilanorandomizedtrialdiabetescare20163920262035 AT niemoellerelisabeth erratumbenefitsoflixilanatitratablefixedratiocombinationofinsulinglarginepluslixisenatideversusinsulinglargineandlixisenatidemonocomponentsintype2diabetesinadequatelycontrolledonoralagentsthelixilanorandomizedtrialdiabetescare20163920262035 AT souhamielisabeth erratumbenefitsoflixilanatitratablefixedratiocombinationofinsulinglarginepluslixisenatideversusinsulinglargineandlixisenatidemonocomponentsintype2diabetesinadequatelycontrolledonoralagentsthelixilanorandomizedtrialdiabetescare20163920262035 AT daviesmelanie erratumbenefitsoflixilanatitratablefixedratiocombinationofinsulinglarginepluslixisenatideversusinsulinglargineandlixisenatidemonocomponentsintype2diabetesinadequatelycontrolledonoralagentsthelixilanorandomizedtrialdiabetescare20163920262035 |